Uncategorized

Leaders at Eli Lilly believe heavy investment in the company’s manufacturing footprint “sets a high standard that newcomers may find challenging to match.” At least one of those newcomers disagrees.

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.

Abbott and Boston Scientific are among the investors in SetPoint, whose neurostimulation device gained FDA approval last month.

High-complexity workups, triage-level pay? Don’t let automated down-coding undervalue your work.

The company, which received investment from the venture capital wing of Intuitive Surgical, has designed the device to work in a broader patient population than existing treatments.

Executives at major for-profit hospital chains gave conflicting answers to explain the softer volumes in the second quarter, from flagging consumer confidence to lower Medicaid admissions. 

Skysona can now only be used in patients with cerebral adrenoleukodystrophy who have no available treatment alternatives or stem cell donors.

Gray Delany was pushed out due to disagreements with other top officials over how the Department of Health and Human Services makes its announcements, according to Endpoints News.

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP-1 offerings. 

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.